products
adjuvants
key ingredients to
effective vaccines
benefits of adjuvants
current vaccine challenges
our solutions
publications
key scientists
vaccines
tb vaccine
leishmaniasis vaccine
leprosy vaccine
diagnostics
tb diagnostics
leishmania diagnostics
leprosy diagnostics
chagas diagnostics
sales contact
therapeutics
tb drug discovery
| |
Leishmaniasis Vaccine
The Challenge
Leishmaniasis is a parasitic disease that occurs in 88 countries around the world. It has an estimated annual incidence of two million cases and a prevalence of 12 million cases. Visceral leishmaniasis, the most severe form of the disease, affects vital organs and has a high fatality rate if not treated. Cutaneous leishmaniasis, the most common form of the disease, causes serious skin lesions and often leaves its victims permanently disfigured. Drugs to treat leishmaniasis are expensive, toxic, or impractical. A safe and efficacious vaccine to control this disease is needed.
Our Solution
IDRI is actively developing vaccines for human and canine leishmaniasis. These vaccines consist of a recombinant Leishmania protein antigen and a T-cell adjuvant. The human vaccine is being evaluated for prophylactic and therapeutic indications in clinical trials in South America, India and Sudan. The canine vaccine is being tested in Brazil, where dogs are an important source of human infection. To date, these studies have shown that the vaccines are safe, well tolerated, immunogenic, and potentially efficacious in the prevention and treatment of diverse forms of leishmaniasis.
Publications
Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 29:3531-3537, 2011.
Nascimento E, Fernandes DF, Vieira EP, Campos-Neto A, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Kahn SJ, Beckmann AM, Pine SO, Cowgill KD, Reed SG, Piazza FM. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 28:6581-6587, 2010.
Trigo J, Abbehusen M, Netto EM, Nakatani M, Pedral-Sampaio G, de Jesus RS, Goto Y, Guderian J, Howard RF, Reed SG. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f +MPL-SE. Vaccine 28:3333-3340, 2010.
Key Scientists
Franco Piazza
Anna Marie Beckman
Rhea Coler
Malcolm Duthie
|
